EVE-106 Novel Estrogen

Product Overview

Alternative Name: EVE-106; EVE106; ethinylestradiol prodrugs

Development Status: Active Development

Target: Female

Mode: Hormonal

Delivery Type: TBD

Duration Type: TBD

Description: EVE-106 is a new chemical entity with validated animal data. A combination of drospirenone (DRSP) and EC-300 (Evestra's test compound), this estrogen receptor agonist is being developed with hopes of utilizing the benefits of DRSP while avoiding the safety issues of ethinyl estradiol (EE).

Updated date: July 19, 2016

Vertical Tabs

Status

Project Phase: Early Development

Project Stage: Pre-clinical

Began discovery in: Prior to 2008

Download Product Report